Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo  >  Shionogi & Co Ltd    4507   JP3347200002


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GSK wins U.S. nod for two-drug HIV combination

share with twitter share with LinkedIn share with facebook
share via e-mail
04/08/2019 | 04:47pm EDT
The GSK logo on the facade of GSK Asia House is seen through vertical louvres in Singapore

(Reuters) - GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

The U.S. Food and Drug Administration cleared the combination of dolutegravir and lamivudine, to be branded as Dovato, for use in newly diagnosed adults.

GSK showed in drug trials last year that the once-a-day Dovato pill was as good as a standard three-drug cocktail in suppressing the virus that causes AIDS and also in terms of tolerability.

GSK's HIV drugs division ViiV, in which Pfizer Inc and Shionogi & Co Ltd have small stakes, will use the lower drug burden as its main selling point to patients and physicians, while hoping that longer-term studies will yield hard evidence of fewer side effects over time.

As HIV positive patients grow older thanks to highly effective treatment, the focus shifts to long-term side effects as nearly half of all HIV patients in the profitable markets of North America and Europe are now over 50.

"We are trying to establish a new normal for people with HIV. We absolutely believe that people living with HIV should not take more medicines than they need," said Deborah Waterhouse, who heads the British drugmaker's HIV unit.

ViiV accounted for about 39 percent of GSK's group operating profit last year, according to UBS analysts. With a 23 percent share in the $26 billion-a-year HIV market, it is seeking to catch up with Gilead's 53 percent.

Gilead will keep up the pressure with new anti-retroviral drug Biktarvy, a combination of three HIV medicines in a daily tablet, which was approved early last year. Market researcher Evaluate pharma expects sales from the product to reach $6.1 billion in 2024.

Hopes for growth - despite harsh competition from Gilead - rest on Dovato as well as on another two-drug combination that will be given as a monthly injection but regulatory approval of the latter is not expected before next year.

The company's growth prospects are clouded by the recent U.S. launch of cheap generic copies of blockbuster asthma treatment Advair, generated 2.4 billion pounds in revenues for GSK last year.

GSK already has two-drug regimen Juluca on the market, but only for the smaller market of HIV patients that have received prior treatment. Dovato is the first such product for new cases.

(Additional reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta and Marguerita Choy)

By Ludwig Burger

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES -1.05% 63.44 Delayed Quote.1.42%
GLAXOSMITHKLINE 0.28% 1669.8 Delayed Quote.11.75%
PFIZER -1.62% 34.61 Delayed Quote.-19.40%
SHIONOGI & CO LTD 0.69% 5831 End-of-day quote.-5.57%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIONOGI & CO LTD
07/22SHIONOGI : Notice of Completion of Disposal of Treasury Shares as Restricted Sto..
07/18SHIONOGI : Notice of Completion of Disposal of Treasury Shares as Restricted Sto..
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
06/23SHIONOGI : Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lu..
06/20SHIONOGI : And ferrer conclude a contract for the promotion in spain of rizmoic,..
06/19SHIONOGI : Announcement about the Adjustment of the Conversion Value for Euro-Ye..
06/19SHIONOGI : Got Approval of Additional Indication of INTUNIV in Japan for Treatme..
06/19SHIONOGI : to Present Cefiderocol and COT-143 Data at American Society for Micro..
06/19SHIONOGI : And ferrer conclude a contract for the promotion in spain of rizmoic®..
More news
Financials (JPY)
Sales 2020 361 B
EBIT 2020 143 B
Net income 2020 129 B
Finance 2020 430 B
Yield 2020 1,71%
P/E ratio 2020 13,6x
P/E ratio 2021 13,5x
EV / Sales2020 3,84x
EV / Sales2021 3,48x
Capitalization 1 815 B
Duration : Period :
Shionogi & Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 7 216,36  JPY
Last Close Price 5 831,00  JPY
Spread / Highest target 50,9%
Spread / Average Target 23,8%
Spread / Lowest Target 9,76%
EPS Revisions
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Kohji Hanasaki Manager-Accounting & Finance
Akio Nomura Independent Director
Teppei Mogi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIONOGI & CO LTD-5.57%17 065
JOHNSON & JOHNSON1.20%349 030
ROCHE HOLDING LTD.12.24%239 457
MERCK AND COMPANY12.09%220 679
NOVARTIS17.81%205 341
PFIZER-19.40%194 582